Alberto Bardelli

Alberto Bardelli was born in Turin on 29 November 1967. He studied Biological Sciences at the University of Turin and received his master's degree in 1991. After graduation, he moved to the Ludwig Institute for Cancer Research in London and obtained a PhD in Biochemistry and Molecular Biology from the University College London (UCL).

From 1999 to 2004, Bardelli has been a postdoctoral researcher at the Johns Hopkins University School of Medicine and the Howard Hughes Medical Institute, Baltimore (MD/USA), in the group led by Bert Vogelstein. Here Bardelli began studying the genomics of cancer. During his postdoctoral training at Johns Hopkins, Bardelli published multiple papers in high-profile journals such as Nature and Science.

In 2004, he returned to Italy as director of a research unit dedicated to the study of tumour genomes at the Candiolo Cancer Institute and Dept. of Oncology, University of Turin.

Since 2016, he has been a full professor of histology at the University of Turin.{{Cite web|publisher=University of Turin|title=Prof. Alberto Bardelli|url=https://www.oncology.unito.it/do/docenti.pl/Alias?alberto.bardelli|access-date=2021-05-14|website=Dipartimento di Oncologia|language=it}}{{Cite web|title=IFOM Alberto Bardelli|url=https://www.ifom.eu/en/cancer-research/researchers/alberto-bardelli.php|access-date=2021-05-14|website=www.ifom.eu}}

From 2018 to 2020, he served as president of the European Association for Cancer Research (EACR).

He is a member of the scientific committee of the Italian Association for Cancer Research (AIRC).{{Cite web|title=Tutti i membri|url=https://www.airc.it/fondazione/chi-siamo/i-nostri-organi-di-governo/tutti-i-membri|access-date=2021-05-14|website=www.airc.it|language=it}}

In 2005, he co-founded the gene editing company Horizon Discovery.

Since April 2022, he has been the scientific director of IFOM, the AIRC Institute of Molecular Oncology, Milan.

Bardelli performed the first comprehensive mutational profile of kinases in colorectal cancers (CRC).{{Cite journal|last1=Bardelli|first1=Alberto|last2=Parsons|first2=D. Williams|last3=Silliman|first3=Natalie|last4=Ptak|first4=Janine|last5=Szabo|first5=Steve|last6=Saha|first6=Saurabh|last7=Markowitz|first7=Sanford|last8=Willson|first8=James K. V.|last9=Parmigiani|first9=Giovanni|last10=Kinzler|first10=Kenneth W.|last11=Vogelstein|first11=Bert|date=2003-05-09|title=Mutational analysis of the tyrosine kinome in colorectal cancers|url=https://pubmed.ncbi.nlm.nih.gov/12738854|journal=Science|volume=300|issue=5621|pages=949|doi=10.1126/science.1082596|issn=1095-9203|pmid=12738854|s2cid=85934154}} He translated these findings into clinical practice by discovering the molecular landscape of response and resistance to EGFR,{{Cite journal|last1=Siravegna|first1=Giulia|last2=Lazzari|first2=Luca|last3=Crisafulli|first3=Giovanni|last4=Sartore-Bianchi|first4=Andrea|last5=Mussolin|first5=Benedetta|last6=Cassingena|first6=Andrea|last7=Martino|first7=Cosimo|last8=Lanman|first8=Richard B.|last9=Nagy|first9=Rebecca J.|last10=Fairclough|first10=Stephen|last11=Rospo|first11=Giuseppe|date=2018-07-09|title=Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer|url=https://pubmed.ncbi.nlm.nih.gov/29990497|journal=Cancer Cell|volume=34|issue=1|pages=148–162.e7|doi=10.1016/j.ccell.2018.06.004|issn=1878-3686|pmid=29990497|s2cid=51611215 |doi-access=free}}{{Cite journal|last1=Siravegna|first1=Giulia|last2=Mussolin|first2=Benedetta|last3=Buscarino|first3=Michela|last4=Corti|first4=Giorgio|last5=Cassingena|first5=Andrea|last6=Crisafulli|first6=Giovanni|last7=Ponzetti|first7=Agostino|last8=Cremolini|first8=Chiara|last9=Amatu|first9=Alessio|last10=Lauricella|first10=Calogero|last11=Lamba|first11=Simona|date=July 2015|title=Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients|journal=Nature Medicine|volume=21|issue=7|pages=795–801|doi=10.1038/nm.3870|issn=1546-170X|pmc=4868598|pmid=26030179}} HER2{{Cite journal|last1=Van Emburgh|first1=Beth O.|last2=Sartore-Bianchi|first2=Andrea|last3=Di Nicolantonio|first3=Federica|last4=Siena|first4=Salvatore|last5=Bardelli|first5=Alberto|date=2014-09-12|title=Acquired resistance to EGFR-targeted therapies in colorectal cancer|journal=Molecular Oncology|volume=8|issue=6|pages=1084–1094|doi=10.1016/j.molonc.2014.05.003|issn=1878-0261|pmc=5528615|pmid=24913799}} and NTRK1{{Cite journal|last1=Russo|first1=Mariangela|last2=Misale|first2=Sandra|last3=Wei|first3=Ge|last4=Siravegna|first4=Giulia|last5=Crisafulli|first5=Giovanni|last6=Lazzari|first6=Luca|last7=Corti|first7=Giorgio|last8=Rospo|first8=Giuseppe|last9=Novara|first9=Luca|last10=Mussolin|first10=Benedetta|last11=Bartolini|first11=Alice|date=January 2016|title=Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer|url=https://pubmed.ncbi.nlm.nih.gov/26546295|journal=Cancer Discovery|volume=6|issue=1|pages=36–44|doi=10.1158/2159-8290.CD-15-0940|issn=2159-8290|pmid=26546295|hdl=2434/342140 |s2cid=33819773 |hdl-access=free}} blockades in CRC. One of the main focuses of his research is the study of the emergence and evolution of drug-resistant clones that can be restrained to improve the efficacy of anticancer agents to develop therapies that adapt to a tumour's evolution.{{Cite journal|last1=Russo|first1=Mariangela|last2=Lamba|first2=Simona|last3=Lorenzato|first3=Annalisa|last4=Sogari|first4=Alberto|last5=Corti|first5=Giorgio|last6=Rospo|first6=Giuseppe|last7=Mussolin|first7=Benedetta|last8=Montone|first8=Monica|last9=Lazzari|first9=Luca|last10=Arena|first10=Sabrina|last11=Oddo|first11=Daniele|date=2018-06-12|title=Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies|journal=Nature Communications|volume=9|issue=1|pages=2287|doi=10.1038/s41467-018-04506-z|issn=2041-1723|pmc=5997733|pmid=29895949|bibcode=2018NatCo...9.2287R}}{{Cite journal|last1=Arena|first1=Sabrina|last2=Siravegna|first2=Giulia|last3=Mussolin|first3=Benedetta|last4=Kearns|first4=Jeffrey D.|last5=Wolf|first5=Beni B.|last6=Misale|first6=Sandra|last7=Lazzari|first7=Luca|last8=Bertotti|first8=Andrea|last9=Trusolino|first9=Livio|last10=Adjei|first10=Alex A.|last11=Montagut|first11=Clara|date=2016-02-03|title=MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations|url=https://pubmed.ncbi.nlm.nih.gov/26843189|journal=Science Translational Medicine|volume=8|issue=324|pages=324ra14|doi=10.1126/scitranslmed.aad5640|issn=1946-6242|pmid=26843189|hdl=10230/26180|s2cid=206689568|hdl-access=free}}{{Cite journal|last1=Misale|first1=Sandra|last2=Bozic|first2=Ivana|last3=Tong|first3=Jingshan|last4=Peraza-Penton|first4=Ashley|last5=Lallo|first5=Alice|last6=Baldi|first6=Federica|last7=Lin|first7=Kevin H.|last8=Truini|first8=Mauro|last9=Trusolino|first9=Livio|last10=Bertotti|first10=Andrea|last11=Di Nicolantonio|first11=Federica|date=2015-09-22|title=Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers|journal=Nature Communications|volume=6|pages=8305|doi=10.1038/ncomms9305|issn=2041-1723|pmc=4595628|pmid=26392303|bibcode=2015NatCo...6.8305M}} His group used several approaches in their work, including genetic analysis of clinical samples, a large collection of CRC cellular models,{{Cite journal|last1=Medico|first1=Enzo|last2=Russo|first2=Mariangela|last3=Picco|first3=Gabriele|last4=Cancelliere|first4=Carlotta|last5=Valtorta|first5=Emanuele|last6=Corti|first6=Giorgio|last7=Buscarino|first7=Michela|last8=Isella|first8=Claudio|last9=Lamba|first9=Simona|last10=Martinoglio|first10=Barbara|last11=Veronese|first11=Silvio|date=2015-04-30|title=The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets|url=https://pubmed.ncbi.nlm.nih.gov/25926053|journal=Nature Communications|volume=6|pages=7002|doi=10.1038/ncomms8002|issn=2041-1723|pmid=25926053|bibcode=2015NatCo...6.7002M|s2cid=205337164 |doi-access=free|hdl=2434/338945|hdl-access=free}} patient-derived xenografts (xenopatients), and liquid biopsies.{{Cite journal|last1=Siravegna|first1=Giulia|last2=Marsoni|first2=Silvia|last3=Siena|first3=Salvatore|last4=Bardelli|first4=Alberto|date=September 2017|title=Integrating liquid biopsies into the management of cancer|url=https://pubmed.ncbi.nlm.nih.gov/28252003|journal=Nature Reviews. Clinical Oncology|volume=14|issue=9|pages=531–548|doi=10.1038/nrclinonc.2017.14|issn=1759-4782|pmid=28252003|s2cid=1478003}}{{Cite journal|last1=Siravegna|first1=Giulia|last2=Bardelli|first2=Alberto|date=March 2016|title=Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients|journal=Molecular Oncology|volume=10|issue=3|pages=475–480|doi=10.1016/j.molonc.2015.12.005|issn=1878-0261|pmc=5528968|pmid=26774880}}{{Cite journal|last1=Bardelli|first1=Alberto|last2=Pantel|first2=Klaus|date=2017-02-13|title=Liquid Biopsies, What We Do Not Know (Yet)|url=https://pubmed.ncbi.nlm.nih.gov/28196593|journal=Cancer Cell|volume=31|issue=2|pages=172–179|doi=10.1016/j.ccell.2017.01.002|issn=1878-3686|pmid=28196593|doi-access=free}} In the last years his studies uncovered the molecular bases of primary and acquired resistance to anti-EGFR therapies in colorectal tumours. These findings have been rapidly translated into clinically applicable predictive biomarkers, which represent the first example of personalized medicine for colorectal tumours and are used to select patients for therapy.{{Cite journal|last=Bardelli|first=Alberto|date=2017-05-24|title=Medical research: Personalized test tracks cancer relapse|url=https://pubmed.ncbi.nlm.nih.gov/28541318|journal=Nature|volume=545|issue=7655|pages=417–418|doi=10.1038/545417a|issn=1476-4687|pmid=28541318|bibcode=2017Natur.545..417B|s2cid=4385197|doi-access=free}}

Bardelli also investigated the use of immunotherapy as a tool for precision medicine in CRC. His studies are built on an unconventional approach that an increased dynamic and mutational load in CRC cells can rouse an otherwise slack immune response, a vital requisite for effective immunosurveillance. Bardelli's team tweaked the clonal evolution of the tumour, via a pharmacological intervention, to provoke the persistent renewal of neoantigens.{{Cite journal|last1=Germano|first1=Giovanni|last2=Lamba|first2=Simona|last3=Rospo|first3=Giuseppe|last4=Barault|first4=Ludovic|last5=Magrì|first5=Alessandro|last6=Maione|first6=Federica|last7=Russo|first7=Mariangela|last8=Crisafulli|first8=Giovanni|last9=Bartolini|first9=Alice|last10=Lerda|first10=Giulia|last11=Siravegna|first11=Giulia|date=2017-12-07|title=Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth|url=https://pubmed.ncbi.nlm.nih.gov/29186113|journal=Nature|volume=552|issue=7683|pages=116–120|doi=10.1038/nature24673|issn=1476-4687|pmid=29186113|bibcode=2017Natur.552..116G|s2cid=205262351}}

Bardelli has authored more than 200 scientific articles, of which 100 were written as an independent investigator. His research papers have been cited over 40,000 times.{{Cite web|title=Scopus preview - Bardelli, Alberto - Author details - Scopus|url=https://www.scopus.com/authid/detail.uri?authorId=7006937523|access-date=2021-05-14|website=www.scopus.com}} Bardelli has been listed as a Highly Cited Researcher in the field of Clinical Medicine in Clarivate Web of Science (2014, 2018–2020).{{Cite web|title=Alberto Bardelli's Publons profile|url=https://publons.com/researcher/1682004/alberto-bardelli/|access-date=2021-05-14|website=publons.com|language=en}}

• 2020 Guido Venosta Award, FIRC AIRC, Presidenza della Repubblica Italiana
• 2019 Elected Member of the Johns Hopkins Society of Scholars{{Cite web|date=2019-04-10|title=Johns Hopkins inducts new members into Society of Scholars|url=https://hub.jhu.edu/2019/04/10/society-of-scholars-induction-ceremony/|access-date=2021-05-14|website=The Hub|language=en}}
• 2017 ESMO Translational Research Award
• 2017 Fellow of European Molecular Biology Organization (EMBO)
• 2015 Fellow of the European Academy of Cancer Sciences{{Cite web|title=Fellows{{!}} European Academy of Cancer Sciences|url=https://www.europeancanceracademy.eu/content/directory.php|access-date=2021-05-14|website=www.europeancanceracademy.eu|archive-date=2019-07-04|archive-url=https://web.archive.org/web/20190704091011/https://www.europeancanceracademy.eu/content/directory.php|url-status=dead}}
• 2015 Fellow of the Turin Academy of Sciences{{Cite web|title=II sezione: scienze della biologia animale e dell'uomo|url=https://www.accademiadellescienze.it/accademia/soci/classe-di-scienze-fisiche-matematiche-e-naturali/soci-corrispondenti/ii-sezione-scienze-della-biologia-animale-e-dell-uomo|access-date=2021-05-14|website=www.accademiadellescienze.it}}

Bardelli was appointed "Officer" of the Order of Merit of the Italian Republic in 2021.{{citation needed|date=April 2022}}

{{Authority control}}

{{DEFAULTSORT:Bardelli, Alberto}}

Category:Italian oncologists

Category:1967 births

Category:Living people

Category:Scientists from Turin

Category:Italian expatriates in the United Kingdom

Category:Alumni of University College London

Category:University of Turin alumni

Category:Officers of the Order of Merit of the Italian Republic